Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT-MDS: Luspatercept vs Epoetin Alfa in Anemia Due to MDS
NCT05949684Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Primary completion
- Mar 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
A Phase 3 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Bristol Myers Squibb. Started Oct 2023; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05949684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949684.